ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2337

Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) and Myositis Autoantibody Groups

Hanna Kim1, Angélique Biancotto2, Foo Cheung3, Terrance P. O'Hanlon4, Ira N. Targoff5, Yan Huang6, Frederick W Miller4, Raphaela Goldbach-Mansky6 and Lisa G Rider4, 1Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, 2Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 3Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 4Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 5VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Biomarkers, juvenile dermatomyositis, pathogenesis and proteomics

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Pediatric Rheumatology – Pathogenesis and Genetics Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease.  Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes within JDM and may indicate distinct pathogeneses.  To define biomarkers and better understand JDM pathogenesis, aptamer-based proteomic technology was used to mine the serum proteome in a well-characterized JDM cohort.

Methods:   Sera from 41 JDM patients (prevalent cases on variable treatment) were selected for relatively high disease activity (physician global activity or PGA median 4.0 (IQR 3.0-5.0)) with anti-TIF1 (n=21), NXP-2 (n=10), and MDA5 MSAs (n=10), and compared with 28 age- and gender-matched healthy controls (HC). Broad proteomic analysis of 1306 targets with a slow off-rate modified aptamer-based assay (SomaLogic, CO) generated simultaneous quantitative serum levels.  Internal discovery/validation was done with 2 independently-analyzed groups each with JDM and HC sera, stratified to evenly distribute PGA, MSA, gender, oral steroid dose (median oral prednisone dose 0.40 mg/kg/day, IQR 0.17-0.73)  and age.  From proteins with Mann Whitney U FDR corrected p values of <0.10 (JDM vs. HC) common to both groups with expression ratio of >1.3, we performed  Ingenuity Pathway Analysis (Qiagen, CA), as well as exploratory Spearman correlation of protein levels versus PGA, also among MSA groups, and protein levels vs. oral steroid dose (mg/kg/day).

Results: 166 proteins met significance criteria in both analysis groups of JDM versus HC sera, with 80 proteins upregulated and 86 downregulated (see Table). Pathway analysis revealed granulocyte/agranulocyte adhesion/diapedesis, interferon, remodeling/damage, Th1, and adipokines as top dysregulated pathway clusters in JDM, even after excluding 4 proteins that correlated with steroid dosage.  We identified 13 proteins with serum levels positively correlated with PGA for JDM overall (rs = 0.31-0.41), 13 proteins in NXP2 Ab group (rs =0.65-0.89), 4 proteins in TIF1 Ab group (rs =0.45-0.54); none in MDA5 Ab group. Individual proteins within MSA groups had stronger correlation with PGA than in JDM overall, and some proteins were only identified in MSA groups (e.g.  IFNB in NXP2 Ab group). 

Conclusion: Broad quantitative proteomic analysis identified key differentiating pathway clusters in JDM versus HC, including some novel proteins. Several protein levels correlated with PGA, with stronger correlation within MSA groups and notable IFN-related proteins upregulated in the NXP2 MSA group.  These proteins identified through a high-throughput screen bring to light pathways that may be important in JDM and potentially MSA-group specific pathogenesis.

This research was supported by the Cure JM Foundation and the Intramural Research Program of the NIH, NIEHS, NHLBI, NIAID, NIAMS and the CC. 


Disclosure: H. Kim, Cure JM Foundation, 2; A. Biancotto, None; F. Cheung, None; T. P. O'Hanlon, None; I. N. Targoff, None; Y. Huang, None; F. W. Miller, None; R. Goldbach-Mansky, None; L. G. Rider, None.

To cite this abstract in AMA style:

Kim H, Biancotto A, Cheung F, O'Hanlon TP, Targoff IN, Huang Y, Miller FW, Goldbach-Mansky R, Rider LG. Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) and Myositis Autoantibody Groups [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/novel-serum-broad-based-proteomic-discovery-analysis-identifies-proteins-and-pathways-dysregulated-in-juvenile-dermatomyositis-jdm-and-myositis-autoantibody-groups/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-serum-broad-based-proteomic-discovery-analysis-identifies-proteins-and-pathways-dysregulated-in-juvenile-dermatomyositis-jdm-and-myositis-autoantibody-groups/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology